Zhang Jianeng, Zhang Huanhuan, Zhou Wenjing, Jiang Meiyan, Lin Xianhua
Reproductive Center, Hangzhou Women's Hospital, Hangzhou, China.
Front Endocrinol (Lausanne). 2025 Mar 21;16:1520362. doi: 10.3389/fendo.2025.1520362. eCollection 2025.
There has been substantial research conducted recently on the effect of myo-inositol (MI) on human reproduction. However, it still remains ambiguous about the therapeutic efficacy of MI in infertile women undergoing fertilization embryo transfer (IVF-ET). This systematic review and meta-analysis was carried out to investigate the efficacy of MI on IVF outcomes.
Literatures were searched in the PubMed, Web of Science, Cochrane Library, ScienceDirect and Wanfang databases. The methodological quality was assessed using the Cochrane Risk of Bias tool. Data were pooled using a random- or fixed-effects model according to study heterogeneity. The results are expressed as odds ratio (OR) or mean difference (MD) with 95% confidence intervals (CIs). Heterogeneity was measured by the I statistic. The protocol was prospectively registered with PROSPERO (CRD42024582149).
Eleven eligible studies with 981 participants reported the IVF outcomes of the MI group versus the control group. The synthesis results showed that the metaphase II (MII) oocyte rate was higher in the MI group than in the control group (OR 1.55, 95% CI 1.04-2.31, =0.03). For polycystic ovary syndrome (PCOS) women, as well as non-obese PCOS women, a statistically significant improvement in MII oocyte rate were assumed after taking MI (OR 1.97, 95% CI 1.20-3.25, <0.01; OR 1.92, 95% CI 1.09-3.37, =0.02) while there is no statistically significant advancement showed in the poor ovary responder (POR) women(OR 0.97, 95% CI 0.35-2.68, =0.95). The fertilization rate was higher in the MI group than in the control group (OR 1.62, 95% CI 1.21-2.16, <0.01), for PCOS, non-obese PCOS and POR women (OR 1.59, 95% CI 1.16-2.18, <0.01; OR 1.87, 95% CI 1.52-2.31, <0.01; OR 2.42, 95% CI 1.48-3.95, <0.01).
Our results suggest that MI supplementation improves the MII oocyte rate and the fertilization rate. More high-grade evidence from prospective randomized studies is warranted.
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024582149.
近期针对肌醇（MI）对人类生殖的影响开展了大量研究。然而，MI对接受体外受精胚胎移植（IVF - ET）的不孕女性的治疗效果仍不明确。本系统评价和荟萃分析旨在研究MI对IVF结局的疗效。
在PubMed、Web of Science、Cochrane图书馆、ScienceDirect和万方数据库中检索文献。使用Cochrane偏倚风险工具评估方法学质量。根据研究异质性，采用随机或固定效应模型合并数据。结果以比值比（OR）或平均差（MD）及95%置信区间（CI）表示。异质性通过I统计量衡量。该方案已在PROSPERO（CRD42024582149）上进行前瞻性注册。
11项纳入981名参与者的合格研究报告了MI组与对照组的IVF结局。综合结果显示MI组的中期II（MII）卵母细胞率高于对照组（OR 1.55，95% CI 1.04 - 2.31，=0.03）。对于多囊卵巢综合征（PCOS）女性以及非肥胖PCOS女性，服用MI后MII卵母细胞率有统计学显著改善（OR 1.97，95% CI 1.20 - 3.25，<0.01；OR 1.92，95% CI 1.09 - 3.37，=0.02），而卵巢反应不良（POR）女性未显示出统计学显著改善（OR 0.97，95% CI 0.35 - 2.68，=0.95）。MI组的受精率高于对照组（OR 1.62，见原文此处有误，应为95% CI 1.21 - 2.16，<0.01），PCOS、非肥胖PCOS和POR女性也是如此（OR 1.59，95% CI 1.16 - 2.18，<0.01；OR 1.87，95% CI 1.52 - 2.31，<0.01；OR 2.42，95% CI 1.48 - 3.95，<0.01）。
我们的结果表明补充MI可提高MII卵母细胞率和受精率。需要更多来自前瞻性随机研究的高级别证据。
https://www.crd.york.ac.uk/PROSPERO/，标识符CRD42024582149 。
原文中“OR 1.62, 95% CI 1.21-2.16, <0.01”中“<0.01”前少了逗号，译文已修正。
